Hoth Therapeutics, Inc. (HOTH), Thursday announced promising data from the first human treatment of epidermal growth factor receptor inhibitor or EGFRI-associated papulopustular eruptions with its novel therapeutic HT-001.
During the study, the company reported significant improvement within one week of initiating therapy in a 59-year-old female undergoing treatment for metastatic breast cancer.
The biotechnology company has also initiated a Phase 2a clinical trial to further evaluate the efficacy and safety of HT-001 in the treatment of EGFRI-associated skin toxicities.
Currently, Hoth's stock is trading at $1.32, up 90.04 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.